{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:36:19Z","timestamp":1782516979126,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We aimed to investigate the effect of antepartum treatment with spiramycin with or without subsequent pyrimethamine\u2013sulfonamide\u2013folinic acid, compared to no treatment, on the rate of mother-to-child transmission (MTCT) of <jats:italic>Toxoplasma gondii<\/jats:italic> (<jats:italic>T. gondii<\/jats:italic>) and incidence\/severity of sequelae in the offspring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Embase and PubMed were searched for literature on spiramycin in pregnant women suspected\/diagnosed with <jats:italic>T. gondii<\/jats:italic> infection. Meta-analyses were performed using random-effects model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-three studies (32 cohorts and 1 cross-sectional study), with a total of 15,406 mothers and 15,250 offspring, were pooled for analyses. The MTCT rate for all treated patients was significantly lower than the untreated [19.5% (95% CI 14\u201325.5%) versus 50.7% (95% CI 31.2\u201370%), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]. The transmission rate in patients on spiramycin monotherapy was also significantly lower than untreated [17.6% (95% CI 9.9\u201326.8%) versus 50.7% (95% CI 31.2\u201370%), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results indicate significant reduction in MTCT rates following spiramycin treatment of suspected\/diagnosed maternal <jats:italic>T. gondii<\/jats:italic> infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-021-00606-7","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T09:02:51Z","timestamp":1639213371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies"],"prefix":"10.1186","volume":"26","author":[{"given":"Jose G.","family":"Montoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Laessig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-3848","authenticated-orcid":false,"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaye","family":"Siliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie S.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Drake-Shanahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Akbary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"issue":"11","key":"606_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/cid\/cis258","volume":"54","author":"R McLeod","year":"2012","unstructured":"McLeod R, Boyer KM, Lee D, Mui E, Wroblewski K, Karrison T, et al. Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981\u20132009). Clin Infect Dis. 2012;54(11):1595\u2013605.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"606_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41426-018-0164-4","volume":"7","author":"K El Bissati","year":"2018","unstructured":"El Bissati K, Levigne P, Lykins J, Adlaoui EB, Barkat A, Berraho A, et al. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerg Microbes Infect. 2018;7(1):165.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"606_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/ciw356","volume":"63","author":"J Lykins","year":"2016","unstructured":"Lykins J, Wang K, Wheeler K, Clouser F, Dixon A, El Bissati K, et al. Understanding toxoplasmosis in the united states through \u201clarge data\u201d analyses. Clin Infect Dis. 2016;63(4):468\u201375.","journal-title":"Clin Infect Dis"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/B0-72-160537-0\/50033-5","volume-title":"Infectious diseases of the fetus and newborn infant","author":"JS Remington","year":"2006","unstructured":"Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, Wilson CB, Baker CJ, editors. Infectious diseases of the fetus and newborn infant. 6th ed. Philadelphia: W.B. Saunders; 2006. p. 947\u20131091.","edition":"6"},{"issue":"4","key":"606_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1086\/590149","volume":"47","author":"JG Montoya","year":"2008","unstructured":"Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554\u201366.","journal-title":"Clin Infect Dis"},{"key":"606_CR6","first-page":"223","volume":"3","author":"R Albouy","year":"1955","unstructured":"Albouy R, Duchesnay G, Eloy P, Pestel M, Ravina A, Rey M. A new French antibiotic: spiramycin. Antibiot Annu. 1955;3:223\u20137.","journal-title":"Antibiot Annu"},{"issue":"6","key":"606_CR7","first-page":"903","volume":"47","author":"J Bogacz","year":"1954","unstructured":"Bogacz J. Comparative effect of various synthetic agents and various antibiotics, including spiramycin, on Toxoplasma. Bull Soc Pathol Exot Filiales. 1954;47(6):903\u201315.","journal-title":"Bull Soc Pathol Exot Filiales"},{"key":"606_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-319-39328-5_5","volume-title":"Infectious diseases in pregnancy. Medical problems during pregnancy","author":"RE Wigmore","year":"2017","unstructured":"Wigmore RE, Salgueiro FM. Infectious diseases in pregnancy. Medical problems during pregnancy. Berlin: Springer; 2017. p. 77\u2013104."},{"issue":"11","key":"606_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/cid\/cis234","volume":"54","author":"A Hotop","year":"2012","unstructured":"Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2012;54(11):1545\u201352.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"606_CR10","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1093\/cid\/ciu724","volume":"60","author":"AR Prusa","year":"2015","unstructured":"Prusa AR, Kasper DC, Pollak A, Gleiss A, Waldhoer T, Hayde M. The Austrian toxoplasmosis register, 1992\u20132008. Clin Infect Dis. 2015;60(2):e4\u201310.","journal-title":"Clin Infect Dis"},{"issue":"9167","key":"606_CR11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(98)08220-8","volume":"353","author":"D Dunn","year":"1999","unstructured":"Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829\u201333.","journal-title":"Lancet"},{"key":"606_CR12","unstructured":"Peyron F, Wallon M, Kieffer F, J.G. G. Toxoplasmosis. In: Wilson CB, Nizet V, Maldonado Y, Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant (Eighth Edition): W.B. Saunders; 2015. p. 949\u20131042."},{"issue":"2 Pt 1","key":"606_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0002-9378(99)70224-3","volume":"180","author":"W Foulon","year":"1999","unstructured":"Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children\u2019s sequelae at age 1 year. Am J Obstet Gynecol. 1999;180(2 Pt 1):410\u20135.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"606_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/ije\/30.6.1303","volume":"30","author":"RE Gilbert","year":"2001","unstructured":"Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn DT. Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol. 2001;30(6):1303\u20138.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"606_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ije\/30.6.1309","volume":"30","author":"L Gras","year":"2001","unstructured":"Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol. 2001;30(6):1309\u201313.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"606_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1470-0328(02)02325-X","volume":"110","author":"R Gilbert","year":"2003","unstructured":"Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG. 2003;110(2):112\u201320.","journal-title":"BJOG"},{"issue":"12","key":"606_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1651-2227.2005.tb01844.x","volume":"94","author":"L Gras","year":"2005","unstructured":"Gras L, Wallon M, Pollak A, Cortina-Borja M, Evengard B, Hayde M, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 2005;94(12):1721\u201331.","journal-title":"Acta Paediatr"},{"issue":"9556","key":"606_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0140-6736(07)60072-5","volume":"369","author":"R Thi\u00e9baut","year":"2007","unstructured":"Thi\u00e9baut R, Leproust S, Ch\u00eane G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients\u2019 data. Lancet. 2007;369(9556):115\u201322.","journal-title":"Lancet"},{"key":"606_CR19","first-page":"1","volume":"138","author":"K Boubaker","year":"2008","unstructured":"Boubaker K, Raeber PA, Vaudaux B, Bucher HC, Garweg JG, Hoesli I, et al. Toxoplasmosis during pregnancy and infancy. A new approach for Switzerland. Swiss Med Wkly. 2008;138:1\u20138.","journal-title":"Swiss Med Wkly."},{"issue":"43\u201344","key":"606_CR20","first-page":"643","volume":"139","author":"R Stricker","year":"2009","unstructured":"Stricker R, Sitavanc R, Liassine N, de Marval F. Toxoplasmosis during pregnancy and infancy. Swiss Med Wkly. 2009;139(43\u201344):643\u20134 (author reply -4).","journal-title":"Swiss Med Wkly."},{"issue":"7","key":"606_CR21","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med."},{"key":"606_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/B978-1-4160-6400-8.00031-6","volume-title":"Infectious diseases of the fetus and newborn","author":"JS Remington","year":"2011","unstructured":"Remington JS, McLeod R, Wilson CB, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, Wilson CB, Nizet V, Maldonado YA, editors. Infectious diseases of the fetus and newborn. 7th ed. Philadelphia: W.B. Saunders; 2011. p. 918\u20131041.","edition":"7"},{"key":"606_CR23","doi-asserted-by":"crossref","unstructured":"Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010;7(10):e1000351.","DOI":"10.1371\/journal.pmed.1000351"},{"key":"606_CR24","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2019. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"3","key":"606_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"606_CR26","doi-asserted-by":"crossref","unstructured":"Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950:607\u201311.","DOI":"10.1214\/aoms\/1177729756"},{"issue":"4","key":"606_CR27","first-page":"138","volume":"32","author":"JJ Miller","year":"1978","unstructured":"Miller JJ. The inverse of the Freeman-Tukey double arcsine transformation. Am Stat. 1978;32(4):138.","journal-title":"Am Stat."},{"issue":"5","key":"606_CR28","doi-asserted-by":"publisher","first-page":"e97775","DOI":"10.1371\/journal.pone.0097775","volume":"9","author":"XL Li","year":"2014","unstructured":"Li XL, Wei HX, Zhang H, Peng HJ, Lindsay DS. A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection. PloS ONE. 2014;9(5):e97775.","journal-title":"PloS ONE."},{"key":"606_CR29","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/B978-1-4557-4801-3.00280-0","volume-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","author":"J Montoya","year":"2015","unstructured":"Montoya J, Boothroyd J, Kovacs J. Toxoplasma gondii. In: Bennett J, Dolin R, Blaser M, editors. Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier; 2015. p. 3122\u201353.","edition":"8"},{"issue":"6","key":"606_CR30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/ije\/30.6.1315","volume":"30","author":"P Thulliez","year":"2001","unstructured":"Thulliez P. Commentary: efficacy of prenatal treatment for toxoplasmosis: a possibility that cannot be ruled out. Int J Epidemiol. 2001;30(6):1315\u20136.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"606_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/eri.12.58","volume":"10","author":"PA Moncada","year":"2012","unstructured":"Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther. 2012;10(7):815\u201328.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"606_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0002-9394(02)01704-X","volume":"135","author":"AP Br\u00e9zin","year":"2003","unstructured":"Br\u00e9zin AP, Thulliez P, Couvreur J, Nobr\u00e9 R, McLeod R, Mets MB. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003;135(6):779\u201384.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"606_CR33","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1128\/JCM.00169-13","volume":"51","author":"H Fricker-Hidalgo","year":"2013","unstructured":"Fricker-Hidalgo H, Cimon B, Chemla C, Darde ML, Delhaes L, L\u2019Ollivier C, et al. Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study. J Clin Microbiol. 2013;51(7):2103\u201311.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"606_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/AOG.0b013e3181d57b09","volume":"115","author":"M Wallon","year":"2010","unstructured":"Wallon M, Franck J, Thulliez P, Huissoud C, Peyron F, Garcia-Meric P, et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol. 2010;115(4):727\u201333.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"606_CR35","doi-asserted-by":"publisher","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","volume":"10","author":"H-X Wei","year":"2015","unstructured":"Wei H-X, Wei S-S, Lindsay DS, Peng H-J. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS ONE. 2015;10(9):e0138204.","journal-title":"PLoS ONE."},{"issue":"4","key":"606_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ajog.2018.05.031","volume":"219","author":"L Mandelbrot","year":"2018","unstructured":"Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(4):386.","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"606_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajog.2018.08.001","volume":"219","author":"JG Montoya","year":"2018","unstructured":"Montoya JG. Systematic screening and treatment of toxoplasmosis during pregnancy: is the glass half full or half empty. Am J Obstet Gynecol. 2018;219(4):315\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"606_CR38","unstructured":"McLeod R, Wheeler K, Boyer K. Congenital Toxoplasmosis. In: Read J, editor. Infectious Diseases of the Fetus and Newborn Infant: Harvard; 2018."},{"key":"606_CR39","first-page":"117","volume-title":"Toxoplasma gondii: the model apicomplexan\u2014perspectives and methods","author":"R McLeod","year":"2019","unstructured":"McLeod R, Cohen W, Dovgin S, Finkelstein L, Boyer KM. Human toxoplasma infection and toxoplasmosis. In: Kim K, Weiss L, editors. Toxoplasma gondii: the model apicomplexan\u2014perspectives and methods. 3rd ed. Cambridge: Academic Press; 2019. p. 117\u2013227.","edition":"3"},{"key":"606_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fcimb.2020.00203","volume":"10","author":"M McPhillie","year":"2020","unstructured":"McPhillie M, Zhou Y, Hickman M, Gordon J, Weber CR, Li Q, et al. Potent tetrahydroquinolone eliminates apicomplexan parasites. Front Cell Infect Microbiol. 2020;10:203.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"606_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-017-0024-6","volume":"2","author":"K El Bissati","year":"2017","unstructured":"El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, et al. Protein nanovaccine confers robust immunity against Toxoplasma. NPJ Vaccines. 2017;2(1):1\u201312.","journal-title":"NPJ Vaccines"},{"issue":"7","key":"606_CR42","doi-asserted-by":"publisher","first-page":"e0005648","DOI":"10.1371\/journal.pntd.0005648","volume":"11","author":"A-R Prusa","year":"2017","unstructured":"Prusa A-R, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. 2017;11(7):e0005648.","journal-title":"PLoS Negl Trop Dis."},{"issue":"12","key":"606_CR43","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/INF.0b013e3182343096","volume":"30","author":"TR Olariu","year":"2011","unstructured":"Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J. 2011;30(12):1056\u201361.","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"606_CR44","doi-asserted-by":"publisher","first-page":"e0005670","DOI":"10.1371\/journal.pntd.0005670","volume":"11","author":"IJ Begeman","year":"2017","unstructured":"Begeman IJ, Lykins J, Zhou Y, Lai BS, Levigne P, El Bissati K, et al. Point-of-care testing for Toxoplasma gondii IgG\/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017;11(6):e0005670.","journal-title":"PLoS Negl Trop Dis."},{"issue":"8","key":"606_CR45","doi-asserted-by":"publisher","first-page":"e0006536","DOI":"10.1371\/journal.pntd.0006536","volume":"12","author":"J Lykins","year":"2018","unstructured":"Lykins J, Li X, Levigne P, Zhou Y, El Bissati K, Clouser F, et al. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-Toxoplasma antibodies. PLoS Negl Trop Dis. 2018;12(8):e0006536.","journal-title":"PLoS Negl Trop Dis."},{"issue":"10","key":"606_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ofid\/ofy215","volume":"5","author":"CA Gomez","year":"2018","unstructured":"Gomez CA, Budvytyte LN, Press C, Zhou L, McLeod R, Maldonado Y, et al. Evaluation of three point-of-care tests for detection of toxoplasma immunoglobulin IgG and IgM in the United States: proof of concept and challenges. Open Forum Infect Dis. 2018;5(10):215.","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"606_CR47","doi-asserted-by":"publisher","first-page":"e0005222","DOI":"10.1371\/journal.pntd.0005222","volume":"11","author":"F Peyron","year":"2017","unstructured":"Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L, et al. Congenital Toxoplasmosis in France and the United States: one parasite, two diverging approaches. PLoS Negl Trop Dis. 2017;11(2):e0005222.","journal-title":"PLoS Negl Trop Dis."},{"key":"606_CR48","doi-asserted-by":"publisher","first-page":"29179","DOI":"10.1038\/srep29179","volume":"6","author":"M McPhillie","year":"2016","unstructured":"McPhillie M, Zhou Y, El Bissati K, Dubey J, Lorenzi H, Capper M, et al. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016;6:29179.","journal-title":"Sci Rep"},{"issue":"9","key":"606_CR49","doi-asserted-by":"publisher","first-page":"e1333","DOI":"10.1371\/journal.pntd.0001333","volume":"5","author":"E Stillwaggon","year":"2011","unstructured":"Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011;5(9):e1333.","journal-title":"PLoS Negl Trop Dis."},{"issue":"3","key":"606_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2016.09.001","volume":"87","author":"C Pomares","year":"2017","unstructured":"Pomares C, Zhang B, Arulkumar S, Gonfrier G, Marty P, Zhao S, et al. Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2017;87(3):213\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"606_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s40124-014-0055-7","volume":"2","author":"R McLeod","year":"2014","unstructured":"McLeod R, Lykins J, Noble AG, Rabiah P, Swisher CN, Heydemann PT, et al. Management of congenital toxoplasmosis. Curr Pediatr Rep. 2014;2(3):166\u201394.","journal-title":"Curr Pediatr Rep"},{"issue":"25","key":"606_CR52","doi-asserted-by":"publisher","first-page":"19600","DOI":"10.2807\/ese.15.25.19600-en","volume":"15","author":"I Villena","year":"2010","unstructured":"Villena I, Ancelle T, Delmas C, Garcia P, Brezin AP, Thulliez P, et al. Congenital toxoplasmosis in France in 2007: first results from a national surveillance system. Euro Surveill. 2010;15(25):19600.","journal-title":"Euro Surveill"},{"issue":"Suppl 1","key":"606_CR53","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/jpids\/piu077","volume":"3","author":"JB McAuley","year":"2014","unstructured":"McAuley JB. Congenital Toxoplasmosis. J Pediatric Infect Dis Soc. 2014;3(Suppl 1):S30\u20135.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"606_CR54","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.parint.2018.07.004","volume":"67","author":"K Khan","year":"2018","unstructured":"Khan K, Khan W. Congenital toxoplasmosis: an overview of the neurological and ocular manifestations. Parasitol Int. 2018;67(6):715\u201321.","journal-title":"Parasitol Int"},{"key":"606_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2334-14-33","volume":"14","author":"MM Avelino","year":"2014","unstructured":"Avelino MM, Amaral WN, Rodrigues IM, Rassi AR, Gomes MB, Costa TL, et al. Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis. 2014;14:33.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"606_CR56","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1017\/S0031182012000765","volume":"139","author":"JP Dubey","year":"2012","unstructured":"Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139(11):1375\u2013424.","journal-title":"Parasitology"},{"issue":"12","key":"606_CR57","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ijpara.2009.04.003","volume":"39","author":"G Pappas","year":"2009","unstructured":"Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385\u201394.","journal-title":"Int J Parasitol"},{"key":"606_CR58","unstructured":"Limonne D, McLeod R, Peyron F, Kamal E-B, Lykins J. Methods and reagents for Toxoplasma infection diagnosis. Google Patents; 2020."}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-021-00606-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00606-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T20:06:00Z","timestamp":1676059560000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-021-00606-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1186\/s40001-021-00606-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a literature review and required no ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Elizabeth Drake-Shanahan and Dr. Chengyue Zhu are currently employed by Sanofi. Dr. Akbar Akbary was employed by Sanofi at the time of this analysis but has since retired. Dr. Mir Sohail Fazeli (Evidinno Outcomes Research Inc.), Sophie Yoon, and Gaye Siliman were contracted by Doctor Evidence LLC, which was contracted by Sanofi to conduct the analysis and medical writing. Dr. Katherine Laessig is employed by Antios Therapeutics and previously served as a consultant to Sanofi and was compensated for this work. Dr. Rima McLeod prepared a literature review pertinent to use of spiramycin and in accordance with Sunshine laws was compensated for this by Sanofi. Dr. McLeod has studied and published results about a point-of-care test which she and colleagues found meets WHO ASSURED criteria for a perfect screening test [\u2013]. This work is currently supported by a grant from The Thrasher Children\u2019s Research Charity Foundation and a Research Seed Grant award from The University of Chicago Global Health Center, and is registered in Clinical Trials.gov. She currently is working without compensation with the FDA, with colleagues at LDBio and in Morocco, to introduce this test for use with FDA clearance and CLIA waiver in the USA. She, with colleagues and The University of Chicago, filed a patent application [] to insure the high quality of this test is sustained. She is working, without compensation, with programs in Morocco [], Colombia [], and Panama [manuscripts in preparation] whose physicians and scientists are now, or will, utilize this testing at scale to help pregnant women and their families in these countries to prevent toxoplasmosis []. Dr. Montoya was an uncompensated consultant in contributing to the literature review. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}